# Beam Therapeutics

key ABE/CBE patents, BEAM-101 (sickle-cell disease).

Source: https://en.bioecon.ru/companies/beam-therapeutics/
Updated: 2026-06-24

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $500 million senior secured credit facility with Sixth Street, with a minimum of $200 million expected to be drawn. | https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-reports-first-quarter-2026-financial-results, https://www.sec.gov/Archives/edgar/data/1745999/000119312526065191/beam-ex99_1.htm, https://www.sec.gov/Archives/edgar/data/1745999/000119312526331522/beam-ex99_1.htm |
| Capacity | Automated process increased capacity by up to three-fold and reduced process duration. | https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-reports-data-highlighting-optimized, https://www.sec.gov/Archives/edgar/data/1745999/000119312526065191/beam-ex99_1.htm |
| Regulatory approval | BEAM-101 (risto-cel) has received U.S. FDA Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation. | https://beamtx.com/pipeline/, https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-us-fda-orphan-drug-designation-0, https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-us-fda-regenerative-medicine-0 |
| Production site | 100,000 square foot cGMP facility in Research Triangle Park, North Carolina. | https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-us-fda-orphan-drug-designation-0, https://www.sec.gov/Archives/edgar/data/1745999/000095017022002166/beam-20211231.htm |
| Headcount | 511 employees as of December 31, 2025. | https://longbridge.com/en/news/276731342.md, https://www.bccresearch.com/company-index/profile/beam-therapeutics, https://www.macrotrends.net/stocks/charts/BEAM/beam-therapeutics/number-of-employees |
| Revenue | $139.74 million for the fiscal year ended December 31, 2025. | https://longbridge.com/en/news/276731342.md, https://www.marketscreener.com/news/beam-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-announces-new-liver-ce7e5cdad88eff21 |

Independent sources: bccresearch.com, beamtx.com, investors.beamtx.com, longbridge.com, macrotrends.net, marketscreener.com, sec.gov

## Technologies

- [Base editing](https://en.bioecon.ru/technology/base-editing/)
- [Genome editing](https://en.bioecon.ru/technology/genome-editing/)